FilingReader Intelligence
Sumitomo Pharma completes Asian business sale, revises outlook
August 1, 2025 at 05:00 AM UTC•By FilingReader AI
Sumitomo Pharma completed the transfer of its Asian business to Marubeni Global Pharma on July 31, generating a pre-tax gain of 45bn yen.
The company projects core operating profit of 70bn yen for the first half of FY2026, including a 14.5bn yen sales milestone and the divestiture gain.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Supplementary Source Documents
(Progress of Disclosure Matters) Completion of Procedures for Company Split of Asian Business and Share Transfer to Marubeni Global PharmaJuly 31, 2025 at 06:30 AM UTC
Consolidated financial results for the first quarter of the fiscal year ending March 2026 [IFRS]July 31, 2025 at 06:30 AM UTC
First quarter financial results for fiscal year 2025 (ending March 2026): financial results presentation materialJuly 31, 2025 at 06:30 AM UTC
Supplementary materials for the first quarter financial results (IFRS) for fiscal year 2025 (ending March 2026)July 31, 2025 at 06:30 AM UTC
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2026 [IFRS]July 31, 2025 at 06:30 AM UTC
Presentation Material (Conference on Q1 FY2025 Financial Results)July 31, 2025 at 06:30 AM UTC
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2026July 31, 2025 at 06:30 AM UTC
Notice regarding the recording of financial expenses (foreign exchange losses)July 31, 2025 at 06:30 AM UTC
Notice Concerning Finance CostsJuly 31, 2025 at 06:30 AM UTC
News Alerts
Get instant email alerts when Sumitomo Dainippon Pharma publishes news
Free account required • Unsubscribe anytime